Streetbeat News

Products Services

AMGN

Amgen (NASDAQ:AMGN) announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS in combination with Vectibix. Both doses demonstrated a statistically significant superiority in progression-free survival over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The results were presented at the ESMO 2023 Congress and published in the New England Journal of Medicine.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:44 pm

MRK

Merck (NYSE:MRK) announced results from the Phase 3 KEYNOTE-A39 trial, conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA plus Padcev. The combination significantly prolonged overall survival by 53% compared to chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. The results were selected for presentation at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:42 pm

JNJ

Janssen, a subsidiary of Johnson & Johnson, announced results from the final analysis of the Phase 3 MAGNITUDE study. The study showed that niraparib, combined with abiraterone acetate and given with prednisone, improved overall survival and time to symptomatic progression in patients with metastatic castration-resistant prostate cancer with BRCA alterations. The data was presented at the European Society for Medical Oncology 2023 Congress.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:36 pm

HOOK

Hookipa Pharma Inc. (NASDAQ:HOOK) has announced preliminary data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with HPV16+ head and neck cancer. The data showed a 42% objective response rate and a disease control rate of 74% across 19 patients, doubling the response rate for pembrolizumab alone. The company plans to start a randomized trial of HB-200 in combination with pembrolizumab as a 1st-line treatment in 2024.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:27 pm

MSFT

PLTR

TSLA

This week in AI news, controversies and investor enthusiasm took center stage. Elon Musk accused Sam Altman of 'stealing' the internet, leading to a Twitter skirmish. AI stocks, including Palantir Technologies and C3.ai, have seen significant growth, but analysts favor one over the other. NYC Mayor Eric Adams has been using AI voice cloning software for multilingual phone calls. A study revealed that AI chatbots can deduce personal details from user inputs, raising privacy concerns. Microsoft CEO Satya Nadella called for philosophical guidance on AI due to fears of manipulation.

Portfolio Pulse from Benzinga Neuro

October 22, 2023 | 12:00 pm

AZN

AstraZeneca announced that its combination of datopotamab deruxtecan and Imfinzi showed robust and durable tumour responses in the first-line treatment of patients with metastatic triple-negative breast cancer in the BEGONIA Phase Ib/II trial. The combination demonstrated a confirmed objective response rate of 79% and no new safety signals were observed. The data will be presented at the European Society for Medical Oncology 2023 Congress.

Portfolio Pulse from Charles Gross

October 22, 2023 | 11:45 am

AAPL

Apple Inc. (NASDAQ:AAPL) had a busy week with developments including TV show cancellations, iPhone 15 Pro Max glitches, CEO Tim Cook's talks with Chinese officials, product timeline updates, and the launch of a new, more affordable Apple Pencil. Apple TV+ cancelled 'The Problem With Jon Stewart' due to creative differences. Apple's customer support suggested that a bug in the iOS 17 beta update might be causing the iPhone 15 Pro Max's display burn-in issue. Amid concerns over a potential iPhone ban and the declining market in China, Tim Cook met with China's commerce minister Wang Wentao. Tech analyst Ming-Chi Kuo suggested that the mass production of Apple's AirTag 2 might be delayed to 2025. Apple launched a new, cost-effective Apple Pencil with a USB-C port.

Portfolio Pulse from Benzinga Neuro

October 22, 2023 | 11:14 am

LLY

NVO

The rising demand for weight-loss medications like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro has led to a surge in counterfeit drugs. Both companies are working with organizations like the Pharmaceutical Security Institute and law enforcement to combat this issue. Counterfeit versions of these drugs have been intercepted in over a dozen countries, posing significant health risks.

Portfolio Pulse from Nabaparna Bhattacharya

October 22, 2023 | 1:56 am

EL

MA

NFLX

UBER

V

Visa Inc. and Mastercard Incorporated are investing billions into African companies to capitalize on the rapid growth of e-commerce in the continent. The investments are focused on mobile money services, which are popular due to the scarcity of conventional banking infrastructures in Africa. The U.S. Commerce Department expects 435 million Africans to make online purchases by the end of the year, nearly double the pre-pandemic level. Mastercard has acquired a minority stake in MTN Group Ltd's fintech business and invested $100 million into Airtel Africa's mobile-money sphere. Visa has pledged to invest $1 billion into Africa over the next five years.

Portfolio Pulse from Nabaparna Bhattacharya

October 22, 2023 | 12:40 am

TSLA

Tesla's Cybertruck recently underwent bulletproof testing, which CEO Elon Musk praised. However, short investor Jim Chanos commented that the summer sun on the truck's stainless steel body might be a bigger concern. Tesla confirmed the Cybertruck's launch date as Nov. 30, but Musk warned that the production ramp-up could be difficult. Tesla's stock ended down 3.69% at $211.99 on Friday.

Portfolio Pulse from Shanthi Rexaline

October 21, 2023 | 9:01 pm